Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): durability and virological response in a large Italian HIV drug resistance network (ARCA)

Dolutegravir (DTG) is a next generation HIV-1 and HIV-2 integrase inhibitor (INI) with potent activity against wild-type and first-generation INI-resistant virus and a high genetic barrier to the development of resistance [1]. The activity of DTG has been demonstrated in several clinical trials, both in drug-naive [2 –4] and experienced subjects [6–8], as well as in subjects who were drug-experienced but INI-naive [9].

Source: Journal of Clinical Virology - June 21, 2018 Category: Virology Authors: S. Rusconi, F. Adorni, P. Tau, V. Borghi, M. Pecorari, R. Maserati, D. Francisci, L. Monno, G. Punzi, P. Meraviglia, S. Paolucci, A. Di Biagio, B. Bruzzone, A. Mancon, V. Micheli, M. Zazzi, on behalf of ARCA (Antiviral Response Cohort Analysis) Source Type: research